Erratum to "European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel" [Eur. Urol. 79(4) (2021) 480-488]
Eur Urol. 2023 May;83(5):e140-e141.
doi: 10.1016/j.eururo.2023.02.007.
Epub 2023 Feb 24.
1 European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. Electronic address: richard.sylvester@skynet.be.
2 Department of Urology, Fundacio Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain.
3 European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
4 Department of Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy.
5 Department of Pathology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic.
6 European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.
7 Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany.
8 Laboratory Medicine Program, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada.
9 Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic.
10 Department of Urology, Fundación Instituto Valenciano de Oncología, Valencia, Spain.
11 Department of Urology, Medical University of Graz, Graz, Austria.
12 Department of Urology, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, The Netherlands; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
13 Department of Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK.
14 Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria.
15 Department of Urology, Pitié Salpétrière Hospital, AP-HP, Sorbonne University, Paris, France.
16 Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
17 Department of Urology, Royal Free London NHS Foundation Trust, Royal Free Hospital, London, UK.
18 Department of Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
19 Department of Urology, Fundacio Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy.
20 Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic.
21 Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.
22 Department of Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada.
23 Department of Pathology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic.
24 Department of Pathology, Fundación Instituto Valenciano de Oncología, Valencia, Spain.
25 Department of Pathology, Medical University of Graz, Graz, Austria.
26 Department of Urology, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, The Netherlands.
27 Department of Pathology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria.
28 Department of Pathology, Pitié Salpétrière Hospital, AP-HP, Pierre et Marie Curie Medical School, Sorbonne University, Paris, France.
29 Department of Pathology, Royal Free London NHS Foundation Trust, Royal Free Hospital, London, UK.
30 Department of Urology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France.
31 Department of Pathology, Fundacio Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain.
32 Department of Pathology, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
33 Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
34 Department of Pathology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy.
35 Department of Pathology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany.
36 Department of Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands.
37 European Association of Urology Guidelines Office, Arnhem, The Netherlands.
38 European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic.
39 European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Fundación Instituto Valenciano de Oncología, Valencia, Spain.
40 European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Royal Free London NHS Foundation Trust, Royal Free Hospital, London, UK.
41 European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Fundacio Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain.
42 European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy.
43 European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany.
44 European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Medical University of Graz, Graz, Austria.
45 European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK.
46 European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic; Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria.
47 European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Pitié Salpétrière Hospital, AP-HP, Sorbonne University, Paris, France.
48 European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Pathology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France.
49 European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada.